Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2021 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
July 15, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Achieves Second Development Milestone from 3D Medicines

HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
July 07, 2021 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that...
June 24, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination with Cabozantinib in Clear Cell Renal Carcinoma

HOUSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
May 18, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Announces Three New Appointments to its Board of Directors

HOUSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the...
May 06, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancerFirst patient dosed in registrational Phase 3 trial...
April 27, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the...
March 16, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates

Initiated a registrational trial of AVB-500 in Platinum Resistant Ovarian Cancer in 1Q 2021First patient dosed in Phase 1b/2 trial of AVB-500 in Clear Cell Renal Cell Carcinoma in 1Q 2021; On-track to...
March 12, 2021 07:00 ET | Source: Aravive, Inc.

Aravive to Present Phase 1b Data Evaluating AVB-500 in Platinum Resistant Ovarian Cancer at 2021 Society of Gynecologic Oncology Annual Meeting

HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b...
March 08, 2021 07:00 ET | Source: Aravive, Inc.

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company has dosed its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right